Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation

Journal of Immunology

Volumn 174, Issue 3, 2005, Pages 1587-1593

  Gosselin, Jean ^a,b   Borgeat, Pierre ^a   Flamand, Louis ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b Fonds de la Rech en S du Quebec   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE B4; PLACEBO; ANTIVIRUS AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HOST RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND; SURVIVAL RATE; VIRUS LOAD; VIRUS REACTIVATION; ANIMAL; BAGG ALBINO MOUSE; BETAHERPESVIRINAE; BONE MARROW TRANSPLANTATION; CYTOLOGY; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG EFFECT; GENETICS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MOUSE MUTANT; PHYSIOLOGY; SPLEEN; TRANSPLANTATION; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ANIMALS; ANTIVIRAL AGENTS; ARACHIDONATE 5-LIPOXYGENASE; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; INJECTIONS, INTRAVENOUS; LEUKOTRIENE B4; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MUROMEGALOVIRUS; SALIVARY GLANDS; SPLEEN; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 12444253835     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.3.1587     Document Type: Article

References (37)

1. Demmler, G. J. 2003. Congenital cytomegalovirus infection treatment. Pediatr. Infect. Dis. J. 22:1005.
2. Meijer, E., G. J. Boland, and L. F. Verdonck. 2003. Prevention of cytomegalovirus disease in recipient of allogeneic stem cell transplants. Clin. Microbiol. Rev. 16:647.
3. Razonable, R. R., and C. V. Paya. 2003. Herpesvirus infection in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10:60.
4. de Maar, E. F., E. A. Verschuuren, M. C. Harmsen, T. H. The, and W. J. van Son. 2003. Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients. Transpl. Infect. Dis. 5:112.
5. Avila-Aguero, M. L., M. M. Paris, W. Alfaro, C. R. Avila-Aguero, and I. Faingezicht. 2003. Ganciclovir therapy in cytomegalovirus (CMV) infection in immunocompetent pediatric patients. Int. J. Infect. Dis. 7:278.
6. Jacobson, M. A. 1998. AIDS-related cytomegalovirus retinitis. Drugs Today 34:409.
7. Ernst, M. E., and R. J. Franey. 1998. Acyclovir- and ganciclovir-induced neurotoxicity. Ann. Pharmacother. 32:111.
8. Scott, J. C., N. Partovi, and M. H. Ensom. 2004. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Theor. Drug Monit. 26:68.
9. Valdez, O., A. Caspar, J. Dickson, A. Weigert, and D. Machado. 2003. Cytomegalovirus infection resistant to ganciclovir in a renal transplant patient. Transplant. Proc. 35:1081.
10. Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866.
11. Yoshikai, Y. 2001. Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection. Curr. Opin. Infect. Dis. 14:257.
12. Ganz, T., M. E. Selsted, D. Szklarek, S. S. Harwig, K. Daher, D. F. Bainton, and R. I. Lehrer. 1985. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. 76:1427.
13. Lehrer, R. I., and T. Ganz. 2002. Defensins of vertebrate animals. Curr. Opin. Immunol. 14:96.
14. 4: an inflammatory mediator in vivo. Prostaglandins 22:213.
15. Bailie, M. B., T. J. Standiford, L. L. Laichald, M. J. Coffey, R. Streiter, and M. Peters-Golden. 1996. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J. Immunol. 157:5221.
16. 4 hydrolase-deficient mice. J. Immunol. 163:6810.
17. 4. Int. J. Immunopharmacol. 11:801.
18. 4 associated with AIDS. AIDS 3:651.
19. Coffey, M. J., S. M. Phare, P. H. Kazanjian, and M. Peters-Golden. 1996. 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J. Immunol. 157:393.
20. Coffey, M. J., S. M. Phare, S. George, M. Peters-Golden, and P. H. Kazanjian. 1998. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J. Clin. Invest. 102:663.
21. + T lymphocytes. J. Exp. Med. 169:1199.
22. Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, and M. J. H. Smith. 1980. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286:264.
23. Smith, M. J. H., A. W. Ford-Hutchinson, and M. A. Bray. 1980. Leukotriene B: a potential mediator of inflammation. J. Pharm. Pharmacol. 32:517.
24. Dahlen, S. E., J. Bjork, P. Hedqvist, K. E. Arfors, S. Hammarstrom, J. A. Lindgren, and B. Samuelsson. 1981. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA 78:3887.
25. 4. Immunology 91:369.
26. 4 augments interleukin-2 receptor-β (IL-2Rβ) expression and IL-2Rβ-mediated cytotoxic response in human peripheral blood lymphocytes. Immunology 76:258.
27. 4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol 4:982.
28. 4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat. Immunol. 4:965.
29. 4 induces interleukin 5 generation from human T lymphocytes. Eur. J. Immunol. 23:2392.
30. 4 enhances activation, proliferation, and differentiation of human B lymphocytes. J. Immunol. 143:1996.
31. 4. Biochim. Biophys. Acta 803:271.
32. 4. J. Pharm. Pharmacol. 33:616.
33. 4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infect. Immun. 69:2011.
34. Mackewicz, C. E., J. Huan, P. Tran, L. Diaz, E. Mack, M. E. Selsted, and J. A. Levy. 2003. α-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17:F23.
35. Zhang, L., W. Yu, T. He, J. Yu, R. E. Caffrey, E. A. Dalmasso, S. Fu, T. Pham, J. Mei, J. J. Ho, et al. 2002. Contribution of human α-defensins-1, -2, and -3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298:995.
36. Flamand, L., P. Borgeat, R. Lalonde, and J. Gosselin. 2004. Release of anti-HIV mediators following leukotriene B4 administration to healthy humans. J. Infect. Dis. 189:2001.
37. Ganz, T., and R. I. Lehrer. 1998. Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. 10:41.